LONDON, Oct 18 (Reuters Breakingviews) - Britain may rue its decision to cancel 100 million doses of a now-promising Covid-19 shot. French biotechnology company Valneva (VLS.PA)said on Monday that its vaccine, which targets the virus in multiple ways, showed promise in a late stage trial and had fewer side effects than the University of Oxford jab developed with AstraZeneca (AZN.L). Valneva’s shares jumped by a third, reversing much of the damage caused by Prime Minister Boris Johnson spiking Britain’s order. Valneva’s shot could be particularly potent. The technology behind it is more traditional, having been tried and tested in ordinary flu vaccines. For holdouts worried about the long-term effects of relatively untested development technologies, this may be a more reassuring option. It also appears to be good value for money. The UK’s order worked out at just over 7 euros per jab, less than half the price of the Pfizer (PFE.N) shot. Britain’s decision to scrap a relatively cheap and effective vaccine is looking foolhardy. (By Aimee Donnellan) On Twitter http://twitter.com/breakingviews Capital Calls - More concise insights on global finance: Real estate distress is tricky call read more Xi Jinping’s COP26 no-show isn’t set in stone read more Bank-software group defers disruption payday read more Gene hunter’s rosier outlook has a downside read more